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Abstract
Background: Thromboangiitis obliterans (TAO, also known as Buerger’s disease) is a non-atherosclerotic inflammatory
vascular disease that primarily affects arteries in the extremities of young adult smokers. Since the etiology of TAO is still
unknown, therapeutic options are limited. Recent attempts in therapeutic angiogenesis have been promising. Therefore,
the aim of our study was to evaluate angiogenic processes and factors including circulating progenitor cells in TAO.
Methodology/Principal Findings: TAO patients with critical limb ischemia and age- and gender-matched nonsmokers and
smokers without cardiovascular disease (n=12 in each group) were enrolled in the study. Flow cytometric analysis of
peripheral blood showed significantly decreased levels of circulating CD45
dimCD34
+ progenitor cells in TAO patients and in
smokers compared to nonsmokers. In contrast to both control groups, the proportion of CD45
dimCD34
+ progenitor cells co-
expressing VEGF receptor-2 (VEGFR2) was significantly elevated in TAO patients. Enzyme-linked immunosorbent assay
(ELISA) of common angiogenic factors (such as VEGF) did not clearly point to pro- or antiangiogenic conditions in serum or
plasma of TAO patients. Serum of TAO patients and controls was evaluated in proliferation, migration (scratch assay) and
spheroid sprouting assays using human umbilical vein endothelial cells (HUVECs). Serum of TAO patients exhibited a
diminished sprouting capacity of HUVECs compared to both control groups. Proliferation and migration of endothelial cells
were impaired after treatment with serum of TAO patients.
Conclusion: Levels of circulating progenitor cells were altered in TAO patients compared to healthy nonsmokers and
smokers. Furthermore, serum of TAO patients exhibited an antiangiogenic activity (impaired endothelial cell sprouting,
migration and proliferation) on endothelial cells, which may contribute to vascular pathology in this patient
population.
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Introduction
Thromboangiitis obliterans (TAO, also known as Buerger’s
disease) is a non-atherosclerotic segmental inflammatory vascular
disease that primarily affects small and medium sized arteries and
veins of the extremities. TAO is observed worldwide with the
highest prevalence in the Middle and Far East. Although the
disease was first described in 1879 the etiology and pathogenesis of
TAO still remains unknown. However, tobacco consumption plays
a key role in the initiation and persistence of the disease. TAO
typically affects young, male smokers, but the incidence in women
is increasing due to tobacco consumption [1,2].
Generally, intermittent claudication is the first clinical symptom
that may progress to critical ischemia with rest pain, digital
gangrene and ulcers, finally resulting in amputation of the affected
extremity. The prognosis of TAO patients is closely related to
smoking. Therefore complete smoking cessation is the most
important therapy for TAO and necessary to prevent disease
progression and to avoid amputation. Beside the local care of
ischemic complications therapeutic options are limited to prosta-
glandins, anticoagulants, anti-inflammatory agents, immunoad-
sorption and sympathectomy. In most cases surgical revascular-
ization is not feasible due to the distal location and diffuse vascular
occlusions in TAO [2–4].
The ischemic condition subsequent to occlusion of the vascular
lumen promotes angiogenesis and arteriogenesis leading to the
development of collaterals in the affected extremities of TAO
patients. A growing number of studies focus on therapeutic
angiogenesis as a treatment strategy in patients with coronary
artery disease, peripheral arterial disease and also in TAO [5]. In a
small clinical trial with TAO patients the intramuscular admin-
istration of recombinant vascular endothelial growth factor (VEGF)
resulted in the healing of ischemic ulcers and relief of rest pain [6].
Increasing evidence suggests that an alteration in stem cell
function plays a role in the pathogenesis of vascular diseases [7].
While pilot studies found promising results after autologous
transplantation of bone marrow mononuclear cells in TAO
patients, little is known about levels of circulating progenitor cells
(PC) subsets in TAO [8–12]. Therefore, the aim of our study was
to evaluate angiogenic processes and factors including circulating
progenitor cells in TAO.
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Materials
Unless otherwise specified, all reagents were purchased from
Sigma Chemical.
Human umbilical vein endothelial cells (HUVECs) were
isolated by collagenase type II (Biochrom KG) digestion of human
umbilical veins by means of standard techniques and cultured in
endothelial cell (EC) medium (MCDB 131, Gibco-BRL Life
Technologies), as described previously [13]. All experiments were
performed with HUVECs from passages 1 to 4.
Study population
For the present study 12 TAO patients were recruited
diagnosed on the basis of established diagnostic criteria (onset of
disease before the age of 50 years, smoking history, affection of
distal arteries, as well as exclusion of atherosclerosis and risk
factors other than smoking) with critical limb ischemia: defined as
chronic ischemic rest pain and/or evidence of ischemic lesions
(either ulcers or gangrene) despite medical therapy. As control
groups we enrolled age- and gender-matched nonsmokers (NS,
n=12) and smokers (S, n=12) without a history of cardiovascular
disease. All study subjects were of European descent and had no
history of malignancy. The study was approved by the Charite ´
University Hospital Ethics Committee and conforms to the
principles outlined in the Declaration of Helsinki. All participants
gave written informed consent to participate in this study.
Study design
All subjects underwent a clinical examination. Blood from the
antecubital vein was collected at 8.00 a.m. after a 12-hour
overnight fast. Serum and plasma samples were separated from
cellular elements by centrifugation and stored at 280uC until
analysis. For analysis of progenitor cells, blood was collected in
EDTA vials and processed immediately. Routine laboratory tests
on blood samples were performed by standard methods in the
hospital’s laboratory.
Transcutaneous measurements of tcPO2 and tcPCO2
To measure tissue oxygenation and carbon-dioxide accumula-
tion, transcutaneous partial oxygen (tcPO2) and carbon-dioxide
pressure (tcPCO2) were determined using a TCM4 device
equipped with a Clark electrode (RadiometerH, Copenhagen,
Denmark). Measurements were taken at the dorsum of both hands
and feet after a resting period of at least 10 minutes, with the
patient in supine position in an air-conditioned room maintained
at 22uC. The calibration period was 10 minutes and the tcPO2/
tcPCO2 signal was continuously recorded for 30 minutes.
Flow cytometric quantification of circulating PCs
Circulating progenitor cells were phenotyped and counted using
flow cytometry following the protocol suggested by Duda et al.
2007 with modifications [14]. Briefly, undiluted blood samples
(0.5 ml) were directly stained and analyzed for phenotypic
expression of surface proteins using pre-conjugated anti-human
monoclonal antibodies: anti-CD45-PacificBlue (Dako), anti-VEGF
receptor-2-PE (R&D Systems), anti-CD34-APC (BD Biosciences),
and anti-CD-133-PE (Miltenyi Biotec). Samples were stained with
antibodies for 15 minutes in the dark. Erythrocytes were lysed
with Easylyse solution (Dako), centrifuged at 200 g for 5 minutes
and fixed in 1 ml 0.2% paraformaldehyde in PBS. For each
sample, 500.000 events were acquired in the peripheral blood
mononuclear cells (PBMC) region using a CyAN-ADP flow
cytometer (Beckman Coulter). Data were analyzed using Summit
4.2 software. The PBMCs were identified using their characteristic
forward and side scatter profile. CD45
dimCD34
+, CD45
dim
CD34
+CD133
+, and CD45
dimCD34
+VEGFR2
+ progenitor cells
were quantified following the gating strategy described by Duda et
al. 2007 [14]. Fluorescence-labeled, isotype-matched nonspecific
immunoglobulin G antibodies served as controls for nonspecific
staining. All instrument settings and the measurement procedure
were stored in a protocol file and remained unchanged throughout
the analyses. The gate on the mononuclear cell populations was set
individually for each sample. The concentrations of progenitor
cells were calculated as ‘‘progenitor cells % PBMCs’’.
Levels of circulating angiogenic factors
In the peripheral blood, serum levels of angiopoietin-1, endoglin,
endostatin, matrix metalloproteinase-8 (MMP-8) and plasma levels
of VEGF were measured using an enzyme-linked immunosorbent
assay (R&D Systems). Detection was performed according to the
manufacturer’s instructions. Each analysis included standard
dilutions, and all samples and dilutions were run in duplicate.
HUVEC proliferation assay
HUVECs were seeded at 8610
4 cells/well in 6-well plates and
cultured in EC medium. After 24 hours cells from two wells were
counted in a hemocytometer and defined as n1 at t1=0 hours.
Medium was replaced by fresh EC medium before treatment. EC
medium was supplemented with 10% serum of subjects and cells
were cultured for additional 24 hours (t2). Adherent cells were
counted in a hemocytometer (n2). Doubling time (tD) was
calculated as tD=log2 (t22t1)/(log n22log n1). Supplementation
of EC medium with 10% fetal calf serum (FCS) served as positive
control. EC medium without serum supplementation was used for
negative control. The experiments were performed in duplicate.
HUVEC spheroid sprouting assay
Spheroids of ,750 HUVECs were generated as previously
described [15]. The HUVEC spheroids were embedded into
collagen gels and incubated at 37uC for 24 hours to polymerize.
EC medium supplemented with 20% serum of subjects was added
to the gel before polymerization started. EC medium without
serum supplementation was used as negative control. The core
plain of at least 3 spheroids per subject was digitally photographed
(Zeiss AxioCam MRc) and in-gel sprouting was analyzed using
Zeiss AxioVision software. HUVEC sprouting was quantified as
sprouting area surrounding the spheroid and expressed in mm
2.
HUVEC migration assay
HUVECs were grown in 24-well plates to a confluent monolayer.
The HUVEC monolayer was scraped in a straight line with a 200 ml
pipettip.Celldebriswasremovedbywashingthecellsoncewith1 ml
of the growth medium and followed by incubation with 1 ml of
medium supplemented with 10% serum of subjects.A reference point
was marked with a tip marker. Dishes were placed under a phase-
contrast microscope (microscopic field: 1.4610
6 mm
2)a n dt h ef i r s t
(baseline)image of thescratchwas acquired.Dishes were incubated in
a tissue culture incubator at 37uC for 6 hours (insufficient time for a
significant number of cells to divide). After the incubation, dishes were
placed under a phase-contrast microscope (matching the reference
point) and a second image was acquired. Images were further
analyzed quantitatively by using Zeiss AxioVision software. The area
covered by cells per view field before and after 6 hours of incubation
was quantified. The difference between areas of the the first and
second image was calculated and expressed as migration area in mm
2.
The assay was performed in triplicate.
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HUVEC viability and cell cycle analysis were performed by
flow cytometry (CyAN-ADP flow cytometer; Beckman Coulter).
HUVECs were seeded at 8610
4 cells/well in 6-well plates and
cultured in EC medium for 24 hours. 10% serum of subjects was
added for 24 hours. Cells were trypsinized and resuspended in
400 ml HEPES buffer containing either 10 mg/ml 7-aminoactino-
mycin D (7-AAD) or 0.05% Triton X-100 and 50 mg/ml
propidium-iodide (PI). Cells positive for 7-AAD were defined as
nonviable. DNA content of the nuclei was measured by red PI
emission for cell cycle analysis. 10.000 events were analyzed for
each sample. The experiments were performed in duplicate.
Statistical Analysis
Data variability about the mean was expressed as the standard
error of the mean (SEM), except where otherwise indicated.
Statistical analysis was performed by one-way ANOVA with post
hoc multiple comparison tests (SPSS v18.0; P,0.05).
Results
Baseline characteristics
The baseline characteristics of TAO patients and control groups
are shown in Table 1. The mean disease duration of TAO patients
at baseline was 5.261.3 years. In their most affected extremity
TAO patients had elevated tcPCO2 (62.362.7 mmHg) and
remarkably reduced tcPO2 (13.663.7 mmHg), indicating severely
impaired tissue oxygenation.
Levels of circulating progenitor cells and PBMCs in TAO
We used four surface markers to identify and enumerate the
following progenitor cell types by flow cytometry:
CD45
dimCD34
+, CD45
dimCD34
+CD133
+, and CD45
dimCD34
+-
VEGFR2
+ progenitor cells. The numbers of progenitor cells were
expressed as cells per 10
5 PBMCs 6 SEM. Levels of circulating
CD45
dimCD34
+ progenitor cells were significantly decreased in
smokers as well as in TAO patients compared to nonsmokers
(81.2623.4, P=0.014 and 60.466.8, P=0.002 vs. 157.3623.4).
TAO patients had slightly lower levels of CD45
dimCD34
+
progenitor cells than smokers but the difference did not reach
statistical significance (P=0.236), (Figure 1A). Similarly,
CD45
dimCD34
+CD133
+ progenitor cell levels were decreased in
smokers and TAO patients compared to nonsmokers (44.4610.6,
P=0.014 and 34.564.7, P=0.002 vs. 76.2610.2) with the lowest
levels measured in TAO patients (Figure 1B). Also the level of
CD45
dimCD34
+VEGFR2
+ cells was significantly reduced in
smokers compared to nonsmokers (1.260.2 vs. 2.160.3,
P=0.028). Strikingly, TAO patients showed a significantly higher
level of this subset of progenitor cells compared to smokers
(2.460.4 vs. 1.260.2, P=0.024), similarly to those of nonsmokers
(Figure 1C). This prompted us to calculate the proportion of
CD45
dimCD34
+VEGFR2
+ progenitor cells relative to the number
of CD45
dimCD34
+ cells. Interestingly, in TAO patients the
proportion of CD45
dimCD34
+VEGFR2
+ progenitor cells was
remarkably elevated compared to both smokers (4.761.0% vs.
2.160.6%, P=0.035) and nonsmokers (4.761.0% vs. 1.560.2%,
P=0.008) (Figure 1D). The average number of PBMCs per ml of
blood did not differ significantly between all 3 groups (nonsmokers
2.2560.21, smokers 2.9460.36, TAO patients 2.7060.18610
6
PBMCs per ml blood) (Figure 1E).
Angiogenic factors in serum and plasma of TAO patients
Common angiogenic factors were evaluated in the peripheral
blood of TAO patients and both control groups by ELISA
(Table 2). There were no significant differences among the 3
groups for serum levels of angiopoietin-1, endoglin, endostatin and
MMP-8. Plasma levels of VEGF tended to be higher in TAO
patients compared to both control groups, but the differences did
not reach statistical significance.
Serum of TAO patients impairs induction of HUVEC
sprouting
An in vitro spheroid sprouting assay with HUVECs was used to
test the angiogenic effect of serum of TAO patients on endothelial
cells. Therefore, HUVEC spheroids were embedded in collagen
gels supplemented with 20% serum of TAO patients or controls
and incubated for 24 hours. The induction of HUVEC sprouting
was impaired in gels supplemented with serum of TAO patients
(0.74610
560.31610
5 mm
2) and smokers (0.94610
560.246
10
5 mm
2) compared to nonsmokers (1.24610
560.37610
5 mm
2,
P=0.001, P=0.058, respectively). Serum of TAO patients
induced less HUVEC sprouting than serum of smokers, but the
difference did not reach statistical significance (P=0.39) (Figure 2).
We also confirmed the antiangiogenic effect of serum of TAO
patients using a rat aortic ring assay. Therein, serum of TAO
patients induced significantly less vascular cell sprouting compared
to serum of nonsmokers and smokers (data not shown).
Serum of TAO patients inhibits HUVEC migration
A HUVEC scratch assay was used to assess the effect of serum
from TAO patients on cell migration. A single scrape was made
across a confluent HUVEC monolayer. The extent of regrowth to
close the scratch wound was measured after 6 hours incubation in
medium containing 10% serum of subjects, an insufficient time for
a significant number of cells to divide. The wound closure at
Table 1. Baseline characteristics of the study groups.
NS
(n=12)
S
(n=12)
TAO
(n=12)
Gender, male/female 9/3 9/3 9/3
Age, years 44.164.8 42.664.8 44.465.1
BMI, kg/m
2 23.263.0 23.763.3 26.964.4{
WBC, /nl 5.161.0 7.763.2* 8.562.3{
C-reactive protein, mg/dl 0.160.1 0.260.1 0.861.6
Tobacco consumption,
pack-years
- 15.569.7 26.669.3{
Current smoking, n - 12 7
Systolic blood pressure, mm Hg 126.7616.8 141.2611.9* 130.4614.0
Diastolic blood pressure, mm Hg 68.666.4 78.268.2* 73.369.5
Total cholesterol, mg/dl 185.6636.1 198.2639.4 190.3654.1
Triglyceride, mg/dl 98.3657.2 139.3683.8 151.3686.7
LDL-cholesterol, mg/dl 113.6626.9 123.0640.7 120.3647.5
HDL-cholesterol, mg/dl 57.9611.9 49.6619.2 41.168.3{
Diabetes, n 0 0 0
Statin, n 0 0 3
*P,0.05 vs. NS;
{P,0.05 vs. NS;
{P,0.05 vs. S; values are mean 6 SD; BMI=body mass index; pack-
years=(packs smoked per day)6(years as a smoker), 1 pack is considered as 20
cigarettes; HDL=high-density lipoprotein; LDL=low-density lipoprotein;
WBC=white blood cell; NS=nonsmokers, S=smokers, TAO=Thromboangiitis
obliterans. All results are presented as mean 6 SD.
doi:10.1371/journal.pone.0034717.t001
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of TAO patients (0.68610
560.24 mm
2) compared to nonsmokers
(3.62610
560.24 mm
2,P ,0.001) and smokers (3.02610
56
0.24 mm
2 P,0.001). There was no significant difference in wound
closure between nonsmokers and smokers (P.0.05) (Figure 3).
Serum of TAO patients inhibits HUVEC proliferation by
changes in cell cycle progression
Next we tested whether impaired HUVEC sprouting induced
by serum of TAO patients is caused by inhibition of endothelial
cell proliferation. HUVECs were cultivated in medium supple-
mented with 10% FCS, before FCS was replaced by 10% serum of
TAO patients and controls. HUVEC proliferation was not
significantly changed with serum of nonsmokers and smokers
compared to FCS, whereas it was impaired with serum of TAO
patients. As shown in Table 3 and Figure 4A, the doubling time
Figure 1. Levels of circulating progenitor cells and PBMCs in TAO patients. Levels of CD45
dimCD34
+, CD45
dimCD34
+CD133
+, and
CD45
dimCD34
+VEGFR2
+ progenitor cells were measured by flow cytometry. The numbers of progenitor cells (PC) were expressed as cells per 10
5
peripheral blood mononuclear cells (PBMCs). A) Levels of CD45
dimCD34
+ PC, B) levels of CD45
dimCD34
+CD133
+ PC, C) levels CD45
dimCD34
+VEGFR2
+
PC, D) proportion of CD45
dimCD34
+VEGFR2
+ PC on CD45
dimCD34
+ PC, E) number of PBMCs per ml of blood. Data are presented as medians, with 25/
75 percentiles (boxes) and 10/90 percentiles (bars), (n=12 in each group). *P,0.05, **P,0.01, ***P,0.001; NS=nonsmokers, S=smokers,
TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.g001
Table 2. Angiogenic factors in TAO.
NS
(n=12)
S
(n=12)
TAO
(n=12)
Angiopoietin-1 (ng/ml) 45.962.9 39.962.6 40.962.9 n.s.
Endoglin (ng/ml) 5.960.2 6.460.3 6.160.4 n.s.
Endostatin (ng/ml) 93.863.6 96.562.7 100.366.5 n.s.
MMP-8 (ng/ml) 10.561.4 16.163.2 18.364.6 n.s.
VEGF (pg/ml) 49.1614.1 52.668.5 63.2615.0 n.s.
MMP-8=matrix metalloproteinase-8, VEGF=vascular endothelial growth factor;
NS=nonsmokers, S=smokers, TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.t002
Angiogenic Factors in TAO
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34717significantly increased to 27.861.5 hours with serum of TAO
patients compared to 21.860.8 hours with serum of smokers and
21.160.6 hours with serum of nonsmokers. Notably, utilizing heat
inactivated (56uC for 60 minutes) serum in the proliferation assay
increased the doubling time for nonsmokers, smokers and TAO
patients to similar levels (31.760.6 vs. 32.160.7 vs.
30.861.4 hours, respectively).
Next, we performed flow cytometric cell cycle analysis to
examine changes in cell cycle progression in HUVECs induced by
serum of TAO patients. Cultivation with serum of TAO patients
for 24 hours increased the population of HUVECs in the G2/M
phase but decreased the population in the G1 phase compared to
HUVECs cultivated with serum of nonsmokers and smokers
(Table 3 and Figure 4B). No distinct sub G1 peak was observed in
any sample, which indicates the absence of apoptosis. Further-
more, 7-AAD labeling revealed that the percentage of non-viable
cells was low and nearly the same in HUVECs treated either with
serum of TAO patients or with serum of both control groups
(Table 3). We also determined the cell size (forward scatter) of
HUVECs during the flow cytometric cell viability analysis. The
average cell size (arbitrary unit) of HUVECs was significantly
increased in TAO patients (153.9960.58) compared to nonsmok-
ers (150.8160.41, P,0.01) and smokers (151.4060.75, P,0.05),
reflecting the higher proportion of cells in the G2/M phase. The
cell size did not differ significantly between nonsmokers and
smokers (P.0.05).
Discussion
There are two major findings in the present study. First, we
found a shift to a higher proportion of CD45
dimCD34
+VEGFR2
+
progenitor cells in TAO patients. Secondly, while angiogenic
factors in plasma/serum of TAO patients did not clearly point to
pro- or antiangiogenic conditions, serum of TAO patients
exhibited a significant antimigratory and antiproliferative effect
on mature endothelial cells in vitro.
While reduced levels and impaired functional activities of
circulating progenitor cells have been described for smokers and
patients with cardiovascular disease, there are only a few studies of
circulating progenitor cells in TAO patients [7,11,12]. In a small
Figure 2. Serum of TAO patients impairs induction of HUVEC sprouting. HUVEC spheroids were embedded in collagen gels supplemented
with 20% serum of TAO patients or controls and incubated for 24 hours. Sprouting was quantified as sprouting area surrounding the spheroid (in
mm
2). Data are presented as medians, with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n=12 in each group). *P,0.05, ***P,0.001;
NS=nonsmokers, S=smokers, TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.g002
Figure 3. Serum of TAO patients inhibits HUVEC migration. Scratch wound closure assay; a single scrape was made across a confluent HUVEC
monolayer (Baseline). The extent of regrowth to close the scratch wound was measured after 6 hours (6 h) incubation in medium containing 10% of
serum of TAO patients or controls. Data are presented as medians, with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n=12 in each group).
***P,0.001; NS=nonsmokers, S=smokers, TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.g003
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differences in the levels of CD45
dimCD34
+VEGFR2
+ progenitor
cells compared to healthy controls [12]. To our knowledge, there
is no study that specifically compares levels of progenitor cells
between TAO patients and a control group of smokers. We
thought to address this by enrolling two control groups in our
study – nonsmokers and smokers without cardiovascular disease –
in addition to a TAO patient group, to dissect out the impact of
smoking from the disease-related effect on CD45
dimCD34
+-
VEGFR2
+ progenitor cells.
The overall population of CD45
dimCD34
+ progenitor cells,
comprising the heterogenic population of hematopoetic stem cell
(HSC) and putative endothelial progenitor cells (EPC), were
significantly decreased in smokers and TAO patients. While the
subset of undifferentiated CD45
dimCD34
+CD133
+ progenitor cells
were decreased in smokers and TAO patients, the subset of
CD45
dimCD34
+VEGFR2
+ progenitor cells, designated as putative
EPCs, were only decreased in smokers but not in TAO patients
[16,17]. Interestingly, although smoking is known to decrease
EPCs [18] and severe smoking is common to smokers and TAO
patients, levels of CD45
dimCD34
+VEGFR2
+ progenitor cells in
TAO patients were similar to levels in nonsmokers. These data
imply a disease-related shift to a higher proportion of
CD45
dimCD34
+VEGFR2
+ progenitor cells within the CD34
+
progenitor cell population in TAO patients. It has been shown that
the cytokine environment determines the differential mobilization
of distinct progenitor cell subsets from the bone marrow. VEGF
suppresses the mobilization of hematopoetic stem cells and
enhances the mobilization of endothelial progenitor cells via
VEGF receptor-2 [19]. The expression of the angiogenic factor
VEGF is induced under ischemic conditions [20]. In fact, small
clinical studies have shown elevated levels of VEGF in TAO
Figure 4. Serum of TAO patients inhibits HUVEC proliferation by changes in cell cycle progression. A) HUVECs were incubated for
24 hours with 10% serum of TAO patients and controls and proliferation was determined as doubling time in hours. Data are presented as medians,
with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n=12 in each group). *P,0.05, **P,0.01, ***P,0.001. B) For cell cycle analysis HUVECs
were cultured for 24 hours with 10% serum of TAO patients and controls, and DNA content was measured by flow cytometry. NS=nonsmokers,
S=smokers, TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.g004
Table 3. Proliferation, viability and cell cycle analysis.
FC
serum
NS
serum
S
serum
TAO
serum P values
Doubling time (h) 22.161.1 21.160.6 21.860.8 27.861.5*{ *P=0.001; {P=0.001
Non-viable cells (%) 3.460.3 3.660.4 3.360.3 3.760.4
G0/1 phase (%) 54.360.5 54.860.9 52.260.8 45.461.6*{ *P,0.001; {P=0.001
S phase (%) 19.460.8 19.860.7 20.460.6 21.560.9
G2/M phase (%) 26.360.6 25.360.8 27.560.4 33.160.7*{ *P,0.001; {P,0.001
*TAO vs. NS,
{TAO vs. S; FC=fetal calf, NS=nonsmokers, S=smokers, TAO=Thromboangiitis obliterans.
doi:10.1371/journal.pone.0034717.t003
Angiogenic Factors in TAO
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might point to a VEGF-mediated increase in CD45
dimCD34
+-
VEGFR2
+ progenitor cells mobilization in response to the
ischemic disease. Notably, it has been shown that patients with
acute myocardial infarction have increased numbers of CD34
+/
VEGFR2
+ progenitor cells, that correlate with plasma VEGF
levels [23]. Pioneering studies about EPCs demonstrated that these
cells contribute to tissue regeneration by promoting angiogenesis
[16,24]. So far, a potential regenerative function of endogenous
EPCs in patients with TAO has not been validated. Noteworthy,
the administration of purified CD34
+/KDR
+ progenitor cells
promoted vascular regeneration in ischemic limbs of mice and
might therefore provide an interesting tool for therapeutic
angiogenesis in ischemic diseases [25]. Pilot studies with TAO
patients showed promising results after autologous bone marrow
mononuclear cell transplantation; however, the contribution of
different progenitor cell subsets remains unclear [8–10]. Further
studies are needed to evaluate the functional consequences of the
shift to CD45
dimCD34
+VEGFR2
+ progenitor cells in TAO
patients.
Tissue resident endothelial cells play a key role in angio-/
arteriogenesis, which is stimulated, at least in part, by circulating
factors [26]. To evaluate the angiogenic potential of serum from
TAO patients and control subjects, we performed in vitro
angiogenesis assays using mature endothelial cells. Our data
showed that serum from TAO patients exhibits a lower angiogenic
capacity as indicated by impaired endothelial cell sprouting
compared to serum of controls. Endothelial cell migration and
proliferation were decreased after treatment with serum from
TAO patients compared to the controls, and were associated with
a modulation of cell cycle progression, while cell viability was
unaffected. This points to an antimitogenic effect of serum of TAO
patients. However, the evaluation of common angiogenic
mediators in serum and plasma did not reveal obvious pro- or
antiangiogenic conditions in TAO patients. VEGF levels tended to
be higher in TAO patients compared to both control groups; but
angiopoietin-1, which acts synergistically with VEGF in angio-
genesis, did not differ significantly between TAO patients and
controls in accordance with a previous publication [12,27]. Levels
of endoglin (CD105), a proangiogenic factor and indicator of
human endothelial cell proliferation [28] and endostatin, a potent
inhibitor of VEGF effects [29], did not differ significantly between
all 3 groups. Taken together, the factor(s) responsible for the
decrease in angiogenic potential of serum from TAO patients
remain(s) to be identified. However, the fact that heat inactivation
of the serums had a more pronounced effect on cell proliferation in
the control groups compared to that of TAO patients points to a
deficiency or lack of proliferation promoting factor(s) in the serum
of TAO patients.
There are some limitations in the present study. The functional
and prognostic relevance of the observed shift to higher levels of
CD45
dimCD34
+VEGFR2
+ cells in TAO patients, and the
functionality of these cells, remain unknown and need to be
elucidated in future studies. Furthermore, an in vivo angiogenesis
model should be used to confirm the data from the in vitro
angiogenesis assays. Future studies should also evaluate factors and
pathways involved in the antimitogenic effect of TAO serum.
In conclusion, TAO patients with peripheral ischemia showed
changes in circulating progenitor subsets. Serum from these
patients exhibited an antimigratory and antiproliferative effect on
mature endothelial cells, which may lead to impaired neovascu-
larization and thus contribute to the acceleration of disease
severity. The observations of the present pilot study have to be
confirmed in larger studies. These studies, together with further
elucidation of angiogenic processes in TAO patients, may provide
new insights into the pathomechanism of the disease and thereby
contribute to the further development of therapeutic angiogenic
strategies.
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